UNSPSC 51111760: Pixantrone

This classification denotes an intercalating agent with the molecular formula C17H19N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5SXN2KNMR, chemically known as 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione but generally known as pixantrone, which bears US NIH Compound Identifier 134019. European Medicines Agency schedules Pixantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21304.

UNSPSC 51111760 Pixantrone is a Commodity code that does not reflect the actual work state and local governments are soliciting under this identifier. The recent opportunities posted under the code involve naloxone procurement, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic pharmaceuticals and OTC products distributed through cooperative purchasing — none of which are pixantrone-specific oncology therapeutics. The code appears to be a mismatch between the UNSPSC taxonomy and the purchasing activity currently tagged to it in state and local procurement systems.

Issuing bodies using this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire and rescue divisions (City of Tampa), and cooperative purchasing alliances serving multi-state public entities (Minnesota Multistate Cooperative Purchasing Alliance with participation from Oregon). The geographic spread includes Florida, Texas, Minnesota, and Oregon, with activity concentrated in cooperative purchasing frameworks that aggregate demand across state and local member agencies. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (posted March 25, 2026, due March 13, 2026, estimated contract value $700,000), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, proposals due March 26, 2026). The mismatch between the code name and actual procurement activity suggests that business development professionals should verify the correct UNSPSC classification before pursuing opportunities under this identifier.